Caitong International Asset Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Caitong International Asset Management’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5	Buy	+3	New	+$5	﹤0.01%	2282

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caitong International Asset Management's LCTX Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in Lineage Cell Therapeutics (LCTX) in Q1 2026: 3 shares worth $5. The stake represents ﹤0.01% of the portfolio and ranks #2282 among its holdings.

130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.

Caitong International Asset Management held 3 shares of Lineage Cell Therapeutics worth $5 as of Q1 2026.
Lineage Cell Therapeutics was a new Caitong International Asset Management position in Q1 2026.
Lineage Cell Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #2282 holding.
130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.